论文部分内容阅读
[目的]明确Kras和Braf蛋白在非小细胞肺癌的表达状况,并探讨其临床意义。[方法]应用免疫组织化学SP法检测126例手术切除非小细胞肺癌组织和其中26例癌旁组织的Kras和Braf蛋白表达情况。分析Kras和Braf蛋白的表达与临床病理学参数之间的关系。[结果]Kras蛋白阳性表达率在肺癌组与癌旁组之间的差异无显著性意义(P>0.05),但在同一病例的癌与癌旁组织中其表达显著相关(r=0.456,P<0.05)。Braf蛋白阳性表达率在肺癌组与癌旁组之间的差异亦无显著性意义(P>0.05),但在不吸烟组显著高于吸烟组(P<0.05);在无淋巴结转移组显著高于淋巴结转移组(P<0.05)。非小细胞肺癌组织中Kras与Braf蛋白的表达无明确相关关系(P>0.05)。[结论]非小细胞肺癌Kras与Braf蛋白在不同患者间的表达存在个体差异,检测Kras与Braf蛋白表达可能有助于筛选酪氨酸激酶受体抑制剂药物治疗的敏感人群。
[Objective] To clarify the expression of Kras and Braf protein in non-small cell lung cancer and to explore its clinical significance. [Method] Immunohistochemical SP method was used to detect the expressions of Kras and Braf protein in 126 cases of resected non-small cell lung cancer and 26 cases of paracancerous tissues. The relationship between Kras and Braf protein expression and clinicopathological parameters was analyzed. [Results] The positive expression rate of Kras protein was not significantly different between lung cancer group and adjacent non-cancerous group (P> 0.05), but there was a significant correlation between the expression of Kras protein and adjacent non-cancerous tissues (r = 0.456, P <0.05). The positive expression rate of Braf protein was also not significantly different between lung cancer group and adjacent non-cancerous lung cancer group (P> 0.05), but significantly higher in non-smoking group than in smoking group (P <0.05), and significantly higher in non-lymph node metastasis group In lymph node metastasis group (P <0.05). There was no significant correlation between Kras expression and Braf protein expression in non-small cell lung cancer (P> 0.05). [Conclusion] The expression of Kras and Braf protein in patients with non-small cell lung cancer has individual differences in different patients. Detection of Kras and Braf protein may be useful in screening susceptible patients with tyrosine kinase receptor inhibitor drug therapy.